Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid

Sorafenib and lenvatinib are multi-targeted tyrosine kinase inhibitors which are currently approved to treat advanced hepatocellular carcinoma, renal cell carcinoma and radioiodine-refractory differentiated thyroid carcinoma. However this treatment is often limited due to common adverse events which...

Descripción completa

Detalles Bibliográficos
Autores principales: Stępniak, Jan, Krawczyk-Lipiec, Joanna, Lewiński, Andrzej, Karbownik-Lewińska, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687109/
https://www.ncbi.nlm.nih.gov/pubmed/36428458
http://dx.doi.org/10.3390/biomedicines10112890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687109/
https://www.ncbi.nlm.nih.gov/pubmed/36428458
http://dx.doi.org/10.3390/biomedicines10112890

Ejemplares similares